BOOKMARK
  • Korean|
  • Chinese|
  • Japanese|
  • Vietnamese
본문내용 바로가기

Aju Business Daily

SEARCH
  • ECONOMY
  • ENTERTAINMENT
  • IT
  • South Korea
  • North Korea
  • WORLD
  • SPORTS
  • LIFESTYLE
  • AUTO MOTIVE
  • OPINION
  • PEOPLE
  • MILITARY
Home > Health > article

Samsung Bioepis demonstrates efficacy of first biosimilar for eye disease treatment

Lim Chang-won Reporter(cwlim34@ajunews.com) | Posted : May 18, 2020, 12:53 | Updated : May 18, 2020, 12:53
  • 트위터
  • 페이스북
  • 웨이보

An image captured from the website of Samsung Bioepisute [Courtesy of Samsung Bioepis]


SEOUL -- Samsung Bioepis, a U.S. and South Korean biopharmaceutical joint venture company, promised to seek a license for the marketing of SB11, a biosimilar candidate referencing Lucentis (ranibizumab), in the United States and Europe saying its efficacy has been demonstrated through final-stage clinical trials.

Ranibizumab, developed by Genentech and marketed by Novartis under the brand name Lucentis, is an anti-angiogenic that has been approved to treat the "wet" type of age-related macular degeneration, a common form of age-related vision loss.

From March 2018 to December 2019, Samsung Bioepis conducted clinical trials on 705 patients with neovascular age-related macular degeneration to compare and study clinical efficacy between SB11 and original medicines. The company said clinical equivalence with original medicines has been demonstrated.

Samsung Bioepis, a joint venture between Biogen, a U.S.-based pharmaceutical company, and Samsung BioLogics, a bio company affiliated with South Korea's largest Samsung Group, said it would apply for a license for SB11's sales in the U.S. and Europe as early as the end of this year. 

"Our first eye disease treatment is expected to provide excellent treatment benefits to patients," an unnamed Samsung Bioepis official was quoted as saying. SB11 is the company's sixth biosimilar and first ophthalmic disease treatment.

Samsung Bioepis has entered into a new commercialization agreement with Biogen for two biosimilar candidates, SB11 and SB15, in the U.S., Canada, Europe, Japan, and Australia. SB15, a biosimilar candidate referencing Eylea (aflibercept), is in pre-clinical development.

Samsung Bioepsis has been known for Imraldi, an adalimumab biosimilar referencing Humira. In 2019, the company won U.S. approval to sell its biosimilar referencing Enbrel (etanercept), one of the best-selling pharmaceutical products, that treats chronic diseases, including moderate to severe rheumatoid arthritis.
 

  • Lim Chang-won Reporter
  • email : cwlim34@ajunews.com
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.
  • twitter
  • facebook
  • weibo
  • link copy
  • LIST
  • TOP

Related news

  • .Samsung Bioepis wins U.S. approval to sell cancer-treating biosimilar .
    Samsung Bioepis wins U.S. approval to sell cancer-treating b…
  • .Court suspends execution of action against Samsung Biologics.
    Court suspends execution of action against Samsung Biologics
  • .Prosecutors raid stock operators office in probe into Samsungs biosimilar arm.
    Prosecutors raid stock operator's office in probe into Samsu…

Real Time Photo News

  • .S. Korea to build state-run K-pop concert hall for unaffordable online performances .

    S. Korea to build state-run K-pop concert hall for unaffordable online performances

  • .BLACKPINK member Rosé to release solo album in March.

    BLACKPINK member Rosé to release solo album in March

  • .BTS agency posts record earnings in 2020 on brisk online activities and album sales .

    BTS agency posts record earnings in 2020 on brisk online activities and album sales

  • .[FOCUS] BTS agency leagues with Universal Music to launch new K-pop band in US music scene.

    [FOCUS] BTS agency leagues with Universal Music to launch new K-pop band in US music scene

  • .CJ ENM aims to become major visual content producer thru partnership with Epic Games .

    CJ ENM aims to become major visual content producer thru partnership with Epic Games

Latest News

more+

  • Aramco partners with Hyundai shipbuilder to develop business model using hydrogen and ammonia
  • Hancom acquires drone technology startup Awesome Tech
  • S. Korea to build state-run K-pop concert hall for unaffordable online performances
  • Busan to set up barrier-free public transportation environments for disabled
  • Hyundai auto group forges hydrogen alliance with SK Group
Aju Business Daily
  • ABOUT US
  • CONTACT US
  • PRIVACY STATEMENT
  • Copyright Policy

Address : Aju News Corporation LEEMA Building, 11th floor, 42, Jong-ro 1-gil, Jongno-gu, Seoul.    Mail : swatchsjp@ajunews.com

Copyright ⓒ 2016 By Ajunews Corporation, All Rights Reserved.

Mobile view